Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 2/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16812491 | 0.98 | YAP1 (0.43) | YAP1TEAD4POLBLMNAF10 | |
| SCHEMBL16794653 | 0.97 | CNR2 (0.41) | YAP1TEAD4POLBF10ALDH1A1 | |
| SCHEMBL16812485 | 0.91 | HPGDS (0.41) | F10CXCR4ALDH1A1PDE1BMEN1 | |
| SCHEMBL16794647 | 0.91 | PDE1B (0.37) | F10CXCR4ALDH1A1PDE1BMEN1 | |
| SCHEMBL16812356 | 0.90 | YAP1 (0.40) | YAP1TEAD4POLBLMNACXCR4 | |
| SCHEMBL16794720 | 0.90 | HPGDS (0.45) | F10PDE1BKMT2AHPGDS | |
| SCHEMBL16812489 | 0.90 | HPGDS (0.45) | F10PDE1BKMT2AHPGDS | |
| SCHEMBL16794721 | 0.90 | HPGDS (0.45) | F10PDE1BKMT2AHPGDS | |
| SCHEMBL31161333 | 0.88 | SSTR3 (0.35) | LMNAF10ALDH1A1PDE1BMEN1 | |
| SCHEMBL31161788 | 0.88 | TYK2 (0.37) | F10PDE1BCNR2TYK2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-11299494-B2 | Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-12 | — | — | US | disclosed |
| CN-110191887-B | Imidazopyridazine modulators of IL-12, IL-23 and/or IFN-alpha | 百时美施贵宝公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3541817-B1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541817-B1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3541817-A1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | Bristol-Myers Squibb Company (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3080131-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2018093968-A1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3080131-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | Bristol-Myers Squibb Company (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | YAP1 780/4885TEAD4 3757/4885POLB 560/4885 |
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | TYK2, JAK3, JAK1 | YAP1 3294/4885TEAD4 865/4885POLB 3098/4885 |
| US-11299494-B2 | Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators | TYK2, IL2, IFNAR1 | YAP1 3876/4885TEAD4 1742/4885POLB 1727/4885 |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | TYK2, IFNAR1, JAK3 | YAP1 4040/4885TEAD4 2078/4885POLB 2551/4885 |
| US-10273237-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses | TYK2, IFNG, IFNAR1 | YAP1 3901/4885TEAD4 2070/4885POLB 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.